Advaxis Appoints David J. Mauro, M.D., Ph.D., as Chief

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Advaxis Appoints David J. Mauro, M.D., Ph.D., as Chief Medical Officer

PRINCETON, N.J., Oct. 20, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed David J. Mauro, M.D., Ph.D., as Executive Vice President, Chief Medical Officer of Advaxis. Dr. Mauro brings to Advaxis more than 14 years of experience in oncology drug development, clinical research, and medical affairs. In his role as Chief Medical Officer, Dr. Mauro will oversee the Company's clinical immuno-oncology programs that utilize bioengineered live attenuated bacteria, Listeria monocytogenes ( Lm ), to actively suppress key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Dr. Mauro most recently served as Executive Director, Section Head Oncology Clinical Development at Merck & Co., Inc. ("Merck"), known as MSD outside the United States and Canada, where he was involved in the strategic oversight and tactical implementation of the clinical development and translational science for multiple programs within the oncology portfolio, including its recently approved PD-1 inhibitor, Keytruda® (pembrolizumab). Prior to joining Merck, Dr. Mauro was Director at Bristol-Myers Squibb Company, where his responsibilities included Erbitux® (cetuximab) Medical Strategy and Oncology Early Development. While at Bristol-Myers Squibb, he was responsible for all life cycle management activities for Erbitux, as well as medical affairs related activities. During his career, Dr. Mauro has participated in multiple FDA submissions and approvals, including three successful new drug applications (NDAs) for Erbitux, Sprycel® (dasatinib) and Sylatron™ (peginterferon alfa-2b), and two PMA filings for EGFR PharmDx and KRAS Companion Diagnostics. Dr. Mauro received his Bachelor of Science in Biochemistry from Cornell University and his medical degree and his doctorate (Ph.D.) in pharmacology from Temple University School of Medicine. He completed his residency training at the National Cancer Institute, National Institutes of Health.

Dr. Mauro will enhance the Advaxis science team, working alongside Dr. Robert Petit, Advaxis's Executive Vice President, and Chief Scientific Officer. Among their joint initiatives, Drs. Petit and Mauro will spearhead a significant expansion of Advaxis research activities targeted toward consolidating the role of Lm -LLO immunotherapies as a valuable component of combination cancer immunotherapy. Specifically, Drs. Petit and Mauro will seek to facilitate translational studies as Advaxis progresses new Lm -LLO treatments and combination immunotherapy regimens from the research labs to the clinic.

"Dr. Mauro brings a wealth of experience overseeing the design, conduct and management of clinical trials," said Daniel J. O'Connor, President and Chief Executive Officer of Advaxis. "His expertise will be essential as we advance the clinical development of our proprietary Lm -LLO cancer immunotherapies and prepare to initiate multiple clinical trials in the coming months. We are proud to have Dr. Mauro join our team and look forward to his contributions as Advaxis establishes its position among the leaders in cancer immunotherapy."

Dr. Mauro will oversee the Company's clinical programs, including the planned Phase 3 clinical trial in cervical cancer, the Phase I/II study with ADXS-HPV in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer, and the Phase I/II study with ADXS-PSA in combination with Merck's approved PD-1 inhibitor, Keytruda, in metastatic, castration-resistant prostate cancer.

"I am excited to join Advaxis at such an important time in the Company's development," stated Dr. Mauro. "I look forward to managing the planned Phase 3 clinical trial in cervical cancer, as well as the early stage monotherapy and combination therapy trials. Overall, I believe there is great potential in the medical community for cancer immunotherapies, and I look forward to advancing Advaxis's unique technology."

In connection with his appointment, Dr. Mauro received a one-time inducement award of 165,000 restricted shares, of which 55,000 (33%) are fully vested and as of the grant date. The remaining shares vest annually over a two-year period. The Board of Directors' Compensation Committee approved the award as an inducement material to Dr. Mauro's entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

About Advaxis, Inc.

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform intended to redirect the immune system to kill cancer. The Advaxis Lm -LLO technology, using bioengineered live attenuated Listeria monocytogenes bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and MSDCs, that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug designation for each of these three indications. The Company plans to initiate a registration clinical program for cervical cancer in 2015 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis is planning to evaluate the combination of ADXS-HPV with an anti-PD-L1 immune checkpoint inhibitor in HPV-associated cervical cancer and head and neck cancer.

Advaxis's second Lm -LLO immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis is planning to file an IND with the FDA and initiate a Phase 1/2 clinical study with ADXS-PSA alone and in combination with a PD-1 checkpoint inhibitor. Advaxis is also developing Lm -LLO immunotherapy ADXS-cHER2, to target the Her2 receptor overexpressing cancers. Her2 is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis is planning to file an IND for ADXS-cHER2 in Her2 overexpressing cancers and to conduct a clinical program in pediatric osteosarcoma. Advaxis has licensed ADXS-cHER2 and three other immunotherapy constructs to Aratana Therapeutics, Inc.

For more information please visit www.advaxis.com .

Forward-Looking Statements

This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS HPV; whether Advaxis immunotherapies can redirect the powerful immune response all human beings have to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov . Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

Keytruda is a registered trademark of Merck & Co.

Sprycel is a registered trademark of Bristol-Myers Squibb Company.

Erbitux is a registered trademark of ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company.

Company: Advaxis, Inc. Greg Mayes, Executive Vice President and COO 609.452.9813 ext. 102 Investors & Media: MDB Communications LLC Michael Becker, President 215.310.5195 ext. 101

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 119

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 114

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 103

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 42

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 7

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Skanska Adds $80M U.S. Tech Facility Contract to Orders

Updated Category News Views 29

An $80 million add-on is the sort of construction news that looks modest until you remember what it says about the customer relationship. Skanska has won an additional contract from an existing client for a U.S. tech facility, worth roughly SEK 760 million, and it will enter U.S. order bookings in the fourth quarter of 2026. No fireworks, no grand strategic...

Continue Reading
Madrigal Pharmaceuticals Faces Legal Scrutiny Over Data

Updated Category News Views 137

Legal Storm Brews for Madrigal Pharmaceuticals Watch out, here comes another storm for Madrigal Pharmaceuticals, folks. This ain't no small drizzle either; it's a full-on legal monsoon, and it's soaked straight through the walls of their executive suite. We're talking a whistleblower sending alarm bells ringing about data fudging and some dodgy boardroom maneuvers—as if...

Continue Reading

Top 5 Most Recently Viewed Articles

Recent Research Highlights the Distress of Captive Elephants

Updated Category News Views 249

Understanding the Distress of Elephants in Captivity A recent peer-reviewed study published in the journal Peer J has shed light on the overwhelming challenges that captive elephants continue to face within zoos despite ongoing efforts to improve conditions. This study stands as a significant testament to the struggles these majestic animals endure, raising essential...

Continue Reading
Exploring the Future of Paper-Based Biofuel Cells Industry

Updated Category News Views 119

Introduction to Paper-Based Biofuel Cells The paper-based biofuel cell (PBFC) market is on the verge of a significant transformation, expected to grow from a valuation of approximately US$ 385.29 million to over US$ 690.23 million by 2033. This remarkable growth reflects an annual growth rate of 7.56% as industries pivot increasingly towards sustainable energy solutions....

Continue Reading
AT&T and Ericsson Fly High with Drone Detection Demo

Updated Category News Views 72

Breaking Down the Drone Detection Demonstration The latest outing from AT&T and Ericsson isn't just tech eye candy—it's a dose of reality wrapped in tomorrow's promise. The goliath telecom duo pulled off a drone detection demo over 5G near AT&T Stadium in Arlington, Texas. What grabs headlines here isn't just the demonstration's success but how it smudges the line...

Continue Reading
Minerva University Launches Innovative Leadership Program in Tokyo

Updated Category News Views 196

Minerva University Launches Innovative Leadership Program The renowned Minerva University has introduced an exciting initiative designed to prepare global executives to effectively navigate today's complex world. The World Wise Executive Leadership Development Program, supported by the Nippon Foundation, focuses on developing leadership skills necessary for thriving in...

Continue Reading
Alpha Omega Partners with USDA to Boost Crop Insurance Support

Updated Category News Views 221

Alpha Omega Secures Contract with USDA to Enhance Crop Insurance Alpha Omega, a leader in digital modernization and cybersecurity, has landed a significant contract with the U.S. Department of Agriculture (USDA). This collaboration is set to enhance the USDA's crop insurance programs, which are essential for safeguarding farmers and ranchers against the growing challenges...

Continue Reading